Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin

Gastroenterology

Volumn 136, Issue 3, 2009, Pages 856-862

  Rossignol, Jean François ^a,b   Elfert, Asem ^c   El Gohary, Yehia ^d   Keeffe, Emmet B ^a,b  

^a Romark Institute for Medical Research   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TANTA UNIVERSITY   (Egypt)

^d ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

NITAZOXANIDE; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG; VIRACURE; VIRUS RNA;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EGYPT; FEMALE; FEVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 60449108708     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.11.037     Document Type: Article

References (15)

1. World Health Organization. Hepatitis C. Fact sheet number 164, revised October 2000. http://www.who.int/mediacentre/factsheets/fs164/en Accessed: May 2, 2008
2. Anderson V.R., and Curran M.P. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 67 (2007) 1947-1967
3. Korba B.E., Montero A.B., Farrar K., et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 77 (2008) 56-63
4. Elazar M., Liu M., McKenna S., et al. Nitazoxanide (NTZ) is an inducer of eIF2a and PKR phosphorylation. (abstr). Hepatology 48 (2008) 1151A
5. Rossignol J.F., Kabil S.M., El-Gohary Y., et al. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 28 (2008) 574-580
6. AIDS Clinical Trials Group. AIDS Clinical Trials Group (ACTG) toxicity grading scale (1996), AIDS Clinical Trials Group, Silver Spring, MD
7. Knodell R.G., Ishak K.J., Black W.C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981) 431-435
8. Goodman Z.K., and Ishak J.G. Histopathology of hepatitis C virus infection. Semin Liver Dis 15 (1995) 71-81
9. Egyptian Ministry of Health. Annual report: 2007. http://www.mohp.gov.eg/main Accessed: May 2, 2008
10. Kamal S.M., and Nasser I.A. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 47 (2008) 1371-1383
11. Legrand-Abravanel F., Nicot F., Boulestin A., et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 77 (2005) 66-69
12. Rossignol J.F., Elfert A., and Keeffe E.B. Evaluation of a 4 week lead-in phase with nitazoxanide (NTZ) prior to peginterferon (PegIFN) plus NTZ for treatment of chronic hepatitis C: final report. (abstr). Hepatology 48 (2008) 344A-345A
13. Rossignol J.F., Elfert A., El-Gohary Y., et al. Randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4. (abstr). J Hepatol 48 Suppl 2 (2008) S30
14. Hoffman P.S., Sission G., Croxen M.A., et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites and Campylobacter jejuni. Antimicrob Agents Chemother 51 (2007) 868-876
15. Korba B.E., Elazar M., Lui P., et al. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother 52 (2008) 4069-4071